Top Markets
Coin of the day
Cyxone AB (publ) Cyxone AB (publ)

Cyxone AB (publ)

CYXO
Rank in Stocks #40403
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing... Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in MalmΓΆ, Sweden.
Share Price
$0.00162013
Last synced: 2025-01-03
Market Cap
$156.25K
Change (1 day)
0.36%
Change (1 year)
0.00%
Country
SE
Trade Cyxone AB (publ) (CYXO)

Category

Operating Margin for Cyxone AB (publ) (CYXO)
Operating Margin as of August 2026 TTM: -420.77%
According to Cyxone AB (publ) latest financial reports and stock price the company's current Operating Margin (TTM) is -420.77%. At the end of 2022 the company had an Operating Margin of -663.15%.
Operating Margin history for Cyxone AB (publ) from 2015 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -420.77% 0.00%
2023 -420.77% -36.55%
2022 -663.15% 0.00%
2021 0.00% 0.00%
2020 0.00% -100.00%
2019 -132,354.43% -91.42%
2018 -1,543,400.00% 0.00%
2017 0.00% -100.00%
2016 -19,798.95% 2,466.53%
2015 -771.43% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.97% -100.09%
US
28.81% -100.07%
NL
0.00% -
CH
0.00% -
KR
31.23% -100.07%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.